Clinical trials: Partial-onset Seizures
Epilepsy, Partial-onset Seizures
Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
EP0024 is a Phase 3, multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) lacosamide (LCM).
- Trial name
- NCT02192814
- Testing
- Lacosamide (200 mg/20 mL)
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy With Partial-onset Seizures
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
The purpose of this trial is to assess the efficacy, safety and tolerability of lacosamide administered as add-on therapy with 1 to 3 anti-seizure medications.
- Trial name
- NCT02477839
- Testing
- Lacosamide
- Where
- 88 sites in United States, Argentina and 24 more
- Volunteers
- 255 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00698581
- Testing
- Brivaracetam
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 88 people
- Sponsor
- UCB Pharma
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00699283
- Testing
- Brivaracetam
- Where
- 68 sites in United States, France and 4 more
- Volunteers
- 62 people
- Sponsor
- UCB Pharma
Epilepsy
A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
Study is conducted to evaluate the long-term safety and tolerability of lacosamide (LCM) in patients receiving LCM in SP0994 [NCT01465997].
- Trial name
- NCT02582866
- Testing
- Lacosamide
- Where
- 46 sites in Bulgaria, Finland and 13 more
- Volunteers
- 106 people
- Sponsor
- UCB Biopharma S.P.R.L.
Highly Drug-resistant Focal Epilepsy
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy.
- Trial name
- NCT02625090
- Testing
- UCB0942
- Where
- 15 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 42 people
- Sponsor
- UCB Biopharma SRL
Epilepsy
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic…
- Trial name
- ALEX-MT (NCT00520741)
- Testing
- Lacosamide
- Where
- 158 sites in United States, Australia and 11 more
- Volunteers
- 426 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Partial Epilepsies
Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure
To evaluate if a flexible dose escalation of lacosamide, up to the maximum approved dose of 400 mg/day, or to a clinically effective lower dose for an individual patient, improves the tolerability and safety of lacosamide (200 mg…
- Trial name
- SELF (NCT01235403)
- Testing
- Lacosamide
- Where
- 32 sites in France
- Volunteers
- 100 people
- Sponsor
- UCB Pharma
Epilepsy With Partial On-set Seizures
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures
- Trial name
- NCT03116828
- Testing
- Eslicarbazepine acetate
- Where
- 55 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Sumitomo Pharma America, Inc.
Epilepsy
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
- Trial name
- NCT00419094
- Testing
- Keppra XR
- Where
- 45 sites in United States, Mexico and 2 more
- Volunteers
- 228 people
- Sponsor
- UCB Pharma
Epilepsy
Eslicarbazepine Acetate Monotherapy Long Term Study
This is a long term, open-label, safety extension study in subjects with partial onset seizures.
- Trial name
- NCT00910247
- Testing
- Eslicarbazepine acetate
- Where
- 122 sites in United States, Bulgaria and 4 more
- Volunteers
- 274 people
- Sponsor
- Sumitomo Pharma America, Inc.
Epilepsy
Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
To assess the long-term effects of levetiracetam on retention rate in subjects with refractory partial onset seizure that are not fully controlled with 1 to 3 concomitant antiepileptic drugs, compared to topiramate as add-on…
- Trial name
- NCT01229735
- Testing
- Levetiracetam, Topiramate
- Where
- 24 sites in South Korea
- Volunteers
- 343 people
- Sponsor
- UCB Korea Co., Ltd.
Epilepsy
Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures
The purpose of this Phase III study is to evaluate the efficacy, safety and tolerability and health outcomes of retigabine Immediate Release (IR) as adjunctive therapy to each of the following monotherapy Antiepileptic Drug (AED)…
- Trial name
- IR (NCT01227902)
- Testing
- Retigabine IR
- Where
- 66 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 203 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
- Trial name
- NCT00464269
- Testing
- Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 400 people
- Sponsor
- UCB Pharma
Epilepsy With POS With or Without Secondary Generalization
Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures
Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard…
- Trial name
- BASE (NCT02687711)
- Where
- 44 sites in Denmark, Germany and 7 more
- Volunteers
- 544 people
- Sponsor
- UCB Biopharma S.P.R.L.
Refractory Partial Onset Seizures
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301.
- Trial name
- NCT00448539
- Testing
- Rufinamide
- Where
- 27 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eisai Inc.
Epilepsy
Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures
The immediate release (IR) formulation of retigabine has been shown to be superior to placebo as adjunctive therapy in 3 adequate and well-controlled studies in subjects with drug-resistant partial-onset seizures (POS) who had…
- Trial name
- NCT01648101
- Testing
- Retigabine 900mg/day, Retigabine 600mg/day
- Where
- 41 sites in Hong Kong, Malaysia and 5 more
- Volunteers
- 76 people
- Sponsor
- GlaxoSmithKline
Drug Resistant Partial Onset Seizure
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).
- Trial name
- NCT01963208
- Testing
- ganaxolone
- Where
- 71 sites in United States, Australia and 4 more
- Volunteers
- 405 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy, Partial
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
- Trial name
- NCT00160654
- Testing
- Levetiracetam
- Where
- 29 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 251 people
- Sponsor
- UCB Pharma
Seizures
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures.
- Trial name
- NCT04244175
- Testing
- CVL-865
- Where
- 76 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- AbbVie